CN117510592A - 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 - Google Patents
一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 Download PDFInfo
- Publication number
- CN117510592A CN117510592A CN202311497539.8A CN202311497539A CN117510592A CN 117510592 A CN117510592 A CN 117510592A CN 202311497539 A CN202311497539 A CN 202311497539A CN 117510592 A CN117510592 A CN 117510592A
- Authority
- CN
- China
- Prior art keywords
- bioactive peptide
- amino acid
- application
- wound
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 38
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 17
- 239000002537 cosmetic Substances 0.000 title claims abstract description 12
- 230000037314 wound repair Effects 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 239000000463 material Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000035876 healing Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 206010052568 Urticaria chronic Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 208000024376 chronic urticaria Diseases 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 4
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 4
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BZSMLNMIDKELJZ-UHFFFAOYSA-N 1-hydroxy-2h-benzotriazol-4-one Chemical compound ON1NN=C2C1=CC=CC2=O BZSMLNMIDKELJZ-UHFFFAOYSA-N 0.000 description 1
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311497539.8A CN117510592B (zh) | 2023-11-11 | 2023-11-11 | 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311497539.8A CN117510592B (zh) | 2023-11-11 | 2023-11-11 | 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117510592A true CN117510592A (zh) | 2024-02-06 |
CN117510592B CN117510592B (zh) | 2024-05-31 |
Family
ID=89758065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311497539.8A Active CN117510592B (zh) | 2023-11-11 | 2023-11-11 | 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117510592B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080241210A1 (en) * | 2007-02-09 | 2008-10-02 | Gene Signal International Sa | Wound healing agent and composition |
CN101547704A (zh) * | 2006-11-13 | 2009-09-30 | 布里格海姆妇女医院公司 | 使用融合至肝素结合序列的生长因子促进心脏修复的方法 |
CA2668580A1 (en) * | 2009-04-30 | 2010-10-30 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR20220020564A (ko) * | 2020-08-12 | 2022-02-21 | 김혜용 | 효과적인 피부재생 및 안티에이징을 위한 미세침, 저분자 펩티드, 천연 추출물을 함유하는 기능성 마이크로 앤 리커버리 화장료 조성물 |
US20220168207A1 (en) * | 2020-11-30 | 2022-06-02 | Quthero, Inc. | Compositions and methods of use for treatment or improvement of the condition and appearance of skin |
CN115505618A (zh) * | 2022-08-31 | 2022-12-23 | 南方海洋科学与工程广东省实验室(广州) | 一种促进皮肤创伤修复的海洋贝类活性肽 |
CN115850381A (zh) * | 2022-12-12 | 2023-03-28 | 中国科学院兰州化学物理研究所 | 一种合成多肽及其在促进皮肤愈合中的应用 |
CN116514911A (zh) * | 2023-04-20 | 2023-08-01 | 永创恒新生物医学科技(北京)有限公司 | 一种多肽及其在制备用于治疗慢性荨麻疹药物中的用途 |
-
2023
- 2023-11-11 CN CN202311497539.8A patent/CN117510592B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101547704A (zh) * | 2006-11-13 | 2009-09-30 | 布里格海姆妇女医院公司 | 使用融合至肝素结合序列的生长因子促进心脏修复的方法 |
US20080241210A1 (en) * | 2007-02-09 | 2008-10-02 | Gene Signal International Sa | Wound healing agent and composition |
CA2668580A1 (en) * | 2009-04-30 | 2010-10-30 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR20220020564A (ko) * | 2020-08-12 | 2022-02-21 | 김혜용 | 효과적인 피부재생 및 안티에이징을 위한 미세침, 저분자 펩티드, 천연 추출물을 함유하는 기능성 마이크로 앤 리커버리 화장료 조성물 |
US20220168207A1 (en) * | 2020-11-30 | 2022-06-02 | Quthero, Inc. | Compositions and methods of use for treatment or improvement of the condition and appearance of skin |
CN115505618A (zh) * | 2022-08-31 | 2022-12-23 | 南方海洋科学与工程广东省实验室(广州) | 一种促进皮肤创伤修复的海洋贝类活性肽 |
CN115850381A (zh) * | 2022-12-12 | 2023-03-28 | 中国科学院兰州化学物理研究所 | 一种合成多肽及其在促进皮肤愈合中的应用 |
CN116514911A (zh) * | 2023-04-20 | 2023-08-01 | 永创恒新生物医学科技(北京)有限公司 | 一种多肽及其在制备用于治疗慢性荨麻疹药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN117510592B (zh) | 2024-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100403750B1 (ko) | 개질된공중합체-1의조성물 | |
CN103533951B (zh) | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 | |
EP2737910B1 (en) | Composite collagen sponge and preparation method thereof | |
CN106084006B (zh) | 一种透皮肽及其应用 | |
CN1997408A (zh) | 包含角蛋白的伤口护理产品 | |
JP2022525126A (ja) | β-エンドルフィンと副腎皮質刺激ホルモンの組み合わせを含む製剤 | |
CN110790822A (zh) | 可模拟血小板衍生因子生物活性的多肽衍生物、纳米纤维及其应用 | |
CN117510592B (zh) | 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用 | |
Younis et al. | Microneedle‐mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune‐Mediated Alopecia | |
BRPI0720874A2 (pt) | Peptídeos bioativosa curtos para modulação celular e imunológica. | |
CN110743034B (zh) | 一种内外协同治疗糖尿病溃疡的多功能水凝胶敷料及其制备方法和应用 | |
CN112625104A (zh) | 一种多肽及其制备方法、应用和药物组合物 | |
CN117582545A (zh) | 一种宫腔修复材料及其制备方法和应用 | |
CN114181295B (zh) | 一种多肽衍生物及其用途、水凝胶及其制备方法 | |
EP4056196A1 (en) | Compositions comprising relaxin and methods of use thereof | |
CN114621323B (zh) | 一类具有皮肤修复作用的多肽化合物及其制备方法和应用 | |
RU2161489C2 (ru) | Усовершенствованный сополимер-1 в сополимерных композициях | |
CA3066214C (en) | Medical preparation for enhancing tissue oxygenation in case of diabetic foot and use of it | |
CN117357693B (zh) | 一种皮肤损伤修复水凝胶敷料及其制备方法 | |
CN109091413A (zh) | 一种透皮性a型肉毒毒素、其制备方法及应用 | |
CN112190687B (zh) | 一种用于减少皮肤创伤瘢痕的药物及其应用 | |
CN114931547B (zh) | 治疗牙槽骨损伤的多肽水凝胶及其制备方法和用途 | |
Nadendla | Second Generation Photoactivated Insulins | |
CN116549621A (zh) | 一种靶向性免疫细胞在制备治疗肿瘤制剂中的应用 | |
CN117323465A (zh) | 一种用于复杂慢性伤口的抗炎组织水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240511 Address after: Room 501, Building 13, No. 488-1 Donghu North Road, Donghu Street, Linping District, Hangzhou City, Zhejiang Province, 310000 (self declared) Applicant after: HANGZHOU DAWEIXIAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Country or region after: China Address before: 81 Shunfu Road, Daxingzhuang Town, Pinggu District, Beijing 101205 Applicant before: Yongchuang Hengxin biomedical technology (Beijing) Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |